Key result
This editorial questions whether the CURE trial results warrant the adjunctive use of clopidogrel with aspirin in patients with acute coronary syndrome without ST-segment elevation.
Why the study?
Does adjunctive use of clopidogrel with aspirin warrant use in patients with acute coronary syndrome without ST elevation?
Does adjunctive use of clopidogrel with aspirin warrant use in patients with acute coronary syndrome without ST elevation?
Answers are grounded in this paper and cite their sources.
Discusses whether the CURE trial results justify the unlicensed use of clopidogrel in patients with non-ST elevation acute coronary syndrome.
Clopidogrel (Plavix-Sanofi-Synthelabo & Bristol-Myers Squibb) blocks platelet aggregation through an action distinct from that of aspirin. In the UK, it is licensed for the secondary prevention of atherosclerotic events and for this, we concluded 3 years ago that clopidogrel "appears to offer no worthwhile advantage over aspirin". After publication of the CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) trial, which assessed adjunctive use of clopidogrel with aspirin in patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-Q wave infarction), clopidogrel was hailed in the lay media as "the biggest breakthrough in 20 years". Do the CURE study results warrant the use of clopidogrel in patients with acute coronary syndrome without ST elevation (currently an unlicensed indication)?
No takes yet. Share an insight, caveat, or question.
A 2002 study conducted an editorial in Acute coronary syndrome without ST-segment elevation. Clopidogrel vs. Aspirin was evaluated. This editorial questions whether the CURE trial results warrant the adjunctive use of clopidogrel with aspirin in patients with acute coronary syndrome without ST-segment elevation.
Synapse has enriched 10 related papers. Consider them for comparative context: